Global health authorities are racing to identify medical options to help contain an Ebola outbreak in eastern Democratic ...
Despite recent advances in immunotherapy and targeted therapy, most patients with non-small-cell lung cancer (NSCLC) continue to have disease progression and develop resistance to current treatments.
In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than standard regimens in relapsed or refractory multiple myeloma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results